Franz-Georg B.
- Country
- Germany
- Department
- Oncology
Research Overview
- Nivolumab in combination with cisplatin and 5-fluorouracil as induction therapy in children and adults with EBV-positive nasopharyngeal carcinoma
- Phase II Multicenter Study of Eftilagimod Alpha and Pembrolizumab in Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Phase III Randomized Study of Adjuvant Datopotamab Deruxtecan and Rilvegostomig Versus Standard Care in Stage I Adenocarcinoma NSCLC with ctDNA-Positive or High-Risk Features
Data & Insights
Has run more than one trial at 39 of 258 partner sites.
Specializations
Oncology - Head and Neck Cancers
This investigator specializes in treating nasopharyngeal carcinoma and head and neck squamous cell carcinoma, with particular expertise in managing EBV-positive cases and exploring innovative therapeutic combinations.
- Advanced nasopharyngeal treatments
- Immunotherapy approaches
- Radiotherapy optimization
Their work encompasses both pediatric and adult populations, focusing on personalized treatment strategies.
Thoracic Oncology
The investigator has developed expertise in treating early-stage non-small cell lung cancer, particularly adenocarcinoma variants, with focus on post-surgical therapeutic interventions.
- Stage I NSCLC management
- Adjuvant therapy development
- Molecular biomarker assessment
Their research integrates circulating tumor DNA analysis for treatment planning.
Hematologic Malignancies
The investigator focuses on various lymphomas, including follicular lymphoma, diffuse large B-cell lymphoma, and Hodgkin lymphoma.
- Novel combination therapies
- Treatment-resistant lymphomas
- Advanced disease management
Their expertise extends to both newly diagnosed and relapsed/refractory cases.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
